ReviewJournal of medical case reports2026
Delayed-type anaphylactic shock to mannitol: a case report and review of the literature.
Review in Journal of medical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMannitol is Food and Drug Administration-approved for the reduction of intracranial pressure associated with cerebral edema and the reduction of intraocular pressure and is a commonly used drug in clinical practice. Hypersensitivity to mannitol is rarely reported, and only nine cases have been documented in English since 1967, all of which exhibited a rapid onset. We report a case of delayed anaphylactic shock induced by mannitol, aiming to alert clinical practitioners to the potential occurrence of such rare and serious adverse drug reactions (ADRs). CASE PRESENTATION: A 62-year-old Asian Chinese male patient was administered mannitol to reduce intraocular pressure following eye trauma. He did not report any discomfort during the first five intravenous infusions of mannitol. However, upon the sixth administration, the patient presented with anaphylactic shock, characterized by an abrupt loss of consciousness and hypotension. In response, the intravenous infusion was promptly discontinued, and a balanced salt solution was administered for fluid replacement. Epinephrine was administered to elevate blood pressure, while dexamethasone was utilized for its properties of inhibiting allergic responses. Subsequently, the patient's level of consciousness and blood pressure stabilized. DISCUSSION: We examined the correlation between anaphylactic shock in patients and mannitol, providing a concise summary of the characteristics noted in previous reports of mannitol-induced allergies. Additionally, we highlighted the distinctions of this particular case through a comprehensive literature review, as well as exploring the potential mechanisms behind delayed drug hypersensitivity reactions attributed to mannitol.
conclusionIt is crucial to be aware of the delayed allergic reactions associated with mannitol. Further post-marketing surveillance studies are necessary to identify rare and unknown adverse drug reactions following therapy with mannitol.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.